Current Report Filing (8-k)
June 08 2023 - 4:31PM
Edgar (US Regulatory)
false 0001622229 0001622229 2023-06-06 2023-06-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 6, 2023
COGENT BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
| Delaware |
|
001-38443 |
|
46-5308248 |
| (State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
| 275 Wyman Street, 3rd Floor Waltham, Massachusetts |
|
02451 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (617) 945-5576
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common stock, $0.001 Par Value |
|
COGT |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 1.01 |
Entry into a Material Definitive Agreement |
On June 6, 2023, Cogent Biosciences, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, Piper Sandler & Co. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 12,500,000 shares of the Company’s common stock at a public offering price of $12.00 per share (the “Offering”).
In addition, the Company granted the Underwriters a 30-day option to purchase up to an additional 1,875,000 shares of its common stock on the same terms and conditions (the “Option”).
The gross proceeds from the Offering are expected to be approximately $150 million before deducting customary underwriting discounts and offering expenses.
The securities described above are offered pursuant to an automatic shelf registration statement (File No. 333-269707) filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 10, 2023. A final prospectus supplement dated June 6, 2023 relating to and describing the terms of the Offering was filed with the SEC on June 8, 2023.
In the Underwriting Agreement, the Company agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute payments that the underwriters may be required to make because of such liabilities.
A copy of the Underwriting Agreement is filed as Exhibits 1.1, and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit.
A copy of the opinion of Gibson, Dunn & Crutcher LLP relating to the validity of the issuance and sale of the shares of the common stock in the Offering is filed herewith as Exhibit 5.1.
| Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| Date: June 8, 2023 |
|
COGENT BIOSCIENCES, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Evan Kearns |
|
|
|
|
|
|
Evan Kearns |
|
|
|
|
|
|
Chief Legal Officer |
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Nov 2023 to Nov 2024
